Status:
UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia
Lead Sponsor:
Taipei Medical University WanFang Hospital
Conditions:
Pneumonia
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18+ years
Brief Summary
Pneumonia is a major infectious cause of death worldwide and imposes a considerable burden on healthcare resources. Obstructive lung diseases (COPD and Asthma) are increasingly important causes of mor...
Detailed Description
The study was a branch of our PM2.5 observational study (Acute Effects of Particulate Matter on Pulmonary Diseases) and mainly focus on lipid biomarker for the target diseases. Lower respiratory tract...
Eligibility Criteria
Inclusion
- Clinical diagnosis of chronic obstructive pulmonary disease (COPD; ICD-9 codes 490-492, 494, 496)
- Clinical diagnosis of Asthma (ICD-9 code 493),
- Clinical diagnosis of pneumonia (ICD-9 codes 480-488).
Exclusion
- Underage incapacity
- Pregnant women,
- Psychiatric history
- Unfamiliar with Chinese
Key Trial Info
Start Date :
March 19 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 19 2021
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03473119
Start Date
March 19 2016
End Date
March 19 2021
Last Update
July 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Emergency Department of Wan Fang Hospital
Taipei, Wenshan District, Taiwan